please click on the headlines below to read the complete article
New Brunswick Government Approves Funding for Pomalyst® - Myeloma Canada applauds New Brunswick’s decision to publicly fund Pomalyst® (pomalidomide) in combination with Decadron® (dexamethasone). Pomalyst® is a treatment option for patients whose disease has progressed despite being treated with traditional therapies. New Brunswick becomes the third jurisdiction after Ontario and Yukon to reimburse Pomalyst®.
Overview of the Myeloma Canada Research Network - The goal of the Myeloma Canada Research Network (MCRN) is to improve patient outcomes by advancing myeloma research across the country. The MCRN is the first and only myeloma research group bringing together Canada’s myeloma research leaders from across Canada. From its beginnings in 2009, it has now grown to a network of over 30 scientists, investigators and clinicians representing 16 myeloma research and treatment centres in nine provinces.
Announcement - Patient Advisory Council - Myeloma Canada is pleased to announce the founding of the Patient Advisory Council (PAC). The Council’s creation was inspired by feedback and comments provided by the patients and caregivers who participated in last year’s pan-Canadian consultation meetings.
Ontario Government Approves Funding for Pomalyst® - Myeloma Canada applauds Ontario’s decision to publicly fund Pomalyst® in combination with Decadron® (dexamethasone). Ontario becomes the first province to reimburse Pomalyst® under the Exceptional Access Program (EAP). Pomalyst® is a treatment option for patients whose disease has progressed despite being treated with traditional therapies.
Criteria updates in the Nova Scotia Formulary regarding Lenalidomide (Revlimid®) - Effective December 29, 2014 - Lenalidomide (Revlimid®) was reviewed by the pCODR Expert Review Committee (pERC) and will be listed with the following new criteria.
ASH 2014: The Latest on Blood Cancers – From Advances to Patient Advantages - On Sunday, December 7, 2014, at 8 p.m., live from San Francisco, where the 56th American Society of Hematology (ASH) Annual Meeting is taking place, leading blood cancer experts, advocacy organizations and patients will put data into perspective, showcasing how scientific advances help patients. A recording of the webcast will be available on December 8th. We will share a link to the webcast shortly.
The news briefing is being hosted by Myeloma Canada, the International Myeloma Foundation, the Lymphoma Research Foundation, the MDS Foundation on behalf of the MDS Alliance and the National Patient Advocate Foundation. Join the conversation around the briefing using the hashtag#BCBrief14
Effective November 18, 2014 - Government is enhancing drug programs by adding 10 new drugs - or new indications for existing drugs - to help Islanders battle disease, says Health and Wellness Minister Doug Currie. Find more information on the Catastrophic Drug Program here.
For those of you who wish to follow the discussion, we will be live tweeting about the Summit and the Awareness Day (@MyelomaCanada). You can also follow the hashtag #makemyelomamatter. Be part of the conversation.
Click here to access the Advocacy Summit Toolkit.
Myeloma Canada is affiliated with the International Myeloma Foundation, the world's oldest and largest myeloma organization
Myeloma Canada gratefully acknowledges the generous unrestricted educational grants from our website sponsors: